Clinical Trial Update: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

View source ↗

Summary

A Travera Inc.-sponsored study evaluated Mass Accumulation Rate as a predictive biomarker in relapsed multiple myeloma; the trial has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Travera Inc | Conditions: Multiple Myeloma in Relapse | Status: TERMINATED